CU20160131A7 - Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas - Google Patents

Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas

Info

Publication number
CU20160131A7
CU20160131A7 CUP2016000131A CU20160131A CU20160131A7 CU 20160131 A7 CU20160131 A7 CU 20160131A7 CU P2016000131 A CUP2016000131 A CU P2016000131A CU 20160131 A CU20160131 A CU 20160131A CU 20160131 A7 CU20160131 A7 CU 20160131A7
Authority
CU
Cuba
Prior art keywords
monobactam
treatment
organic compounds
bacterial infections
compounds
Prior art date
Application number
CUP2016000131A
Other languages
English (en)
Other versions
CU24441B1 (es
Inventor
Virender Sigh Aulakh
Anthony Casarez
Xiaodong Lin
Mika Lindvall
Glenn Mcenroe
Heinz Ernst Moser
Folkert Reck
Meiliana Tjandra
Robert Lowell Simmons
Aregahegn Yifru
Qingming Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20160131A7 publication Critical patent/CU20160131A7/es
Publication of CU24441B1 publication Critical patent/CU24441B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere en general a compuestos antibacterianos de Ia Formula I, ESPACIO PARA FÓRMULA como se describe adicionalmente en este documento, y las sales y formulaciones farmacéuticamente aceptables de los mismos. En ciertos aspectos, Ia invención se refiere a métodos de uso de tales compuestos para tratar infecciones tales como las causadas por bacterias Gram-negativas.
CU2016000131A 2014-03-24 2015-03-23 Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas CU24441B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969735P 2014-03-24 2014-03-24
US201462088304P 2014-12-05 2014-12-05
PCT/US2015/022011 WO2015148379A1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CU20160131A7 true CU20160131A7 (es) 2017-02-02
CU24441B1 CU24441B1 (es) 2019-09-04

Family

ID=52808201

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000131A CU24441B1 (es) 2014-03-24 2015-03-23 Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas

Country Status (37)

Country Link
US (4) US9174978B2 (es)
EP (2) EP3122745B1 (es)
JP (1) JP6153674B2 (es)
KR (1) KR101733441B1 (es)
CN (1) CN106164072B (es)
AP (1) AP2016009374A0 (es)
AU (1) AU2015236369B2 (es)
BR (1) BR112016020333B1 (es)
CA (1) CA2939254C (es)
CL (1) CL2016002285A1 (es)
CU (1) CU24441B1 (es)
CY (1) CY1121701T1 (es)
DK (2) DK3122745T3 (es)
EA (1) EA030850B1 (es)
EC (1) ECSP16073620A (es)
ES (2) ES2719136T3 (es)
GT (1) GT201600183A (es)
HR (1) HRP20190501T1 (es)
HU (1) HUE042134T2 (es)
IL (1) IL247259B (es)
LT (1) LT3122745T (es)
MA (1) MA39777B1 (es)
MX (1) MX373444B (es)
MY (1) MY179292A (es)
PE (1) PE20161371A1 (es)
PH (1) PH12016501577B1 (es)
PL (1) PL3122745T3 (es)
PT (1) PT3122745T (es)
RS (1) RS58509B1 (es)
SG (1) SG11201606711UA (es)
SI (1) SI3122745T1 (es)
SM (1) SMT201900218T1 (es)
SV (1) SV2016005274A (es)
TW (1) TWI714525B (es)
UA (1) UA121383C2 (es)
WO (1) WO2015148379A1 (es)
ZA (1) ZA201605565B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092620A1 (ru) * 2015-09-23 2021-06-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
US20180282331A1 (en) 2015-11-09 2018-10-04 Wockhardt Limited 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS
KR20180093925A (ko) * 2015-12-15 2018-08-22 머크 샤프 앤드 돔 코포레이션 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법
MX2018010878A (es) 2016-03-07 2018-11-09 Merck Sharp & Dohme Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
SG11201908691PA (en) 2017-03-20 2019-10-30 Broad Inst Inc Compounds and methods for the treatment of parasitic diseases
AU2018311521B2 (en) * 2017-08-02 2022-03-03 Novartis Ag Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
WO2019058346A1 (en) * 2017-09-22 2019-03-28 Novartis Ag MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
US10280161B2 (en) * 2017-10-02 2019-05-07 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
MA50629A (fr) 2017-10-02 2021-03-31 Merck Sharp & Dohme Composés monobactames de chromane pour le traitement d'infections bactériennes
EP3706738A1 (en) * 2017-11-10 2020-09-16 Novartis AG Administration of monobactam for the treatment of urinary tract infection
US11459323B2 (en) 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection
KR102017784B1 (ko) * 2018-04-11 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
KR102017785B1 (ko) * 2018-05-17 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
KR20210083285A (ko) 2018-11-13 2021-07-06 난징 산홈 팔마세우티칼 컴퍼니 리미티드 모노박탐 화합물 및 그의 사용
WO2020125670A1 (zh) * 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
EP4046998B1 (en) * 2019-11-22 2024-02-28 Suzhou Erye Pharmaceutical Co., Ltd. Sulfonylurea ring substituted monocyclic beta-lactam antibiotics
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
EP3838266A1 (en) 2019-12-20 2021-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN115210231B (zh) * 2020-07-16 2024-10-08 宁夏农林科学院 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
CR20240212A (es) 2021-11-18 2024-07-01 Merck Sharp & Dohme Llc Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205240A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Sulphonamide derivatives,being starting materials for producing beta-lactams
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
US4782147A (en) * 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
JPS58189176A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd １−スルホ−２−アゼチジノン誘導体およびその製造法
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
AU564150B2 (en) 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP4440344B2 (ja) 1996-08-16 2010-03-24 シェーリング コーポレイション 哺乳動物細胞表面抗原；関連試薬
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
WO2001003720A2 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
MXPA05012475A (es) 2003-05-23 2006-05-25 Wyeth Corp Anticuerpos y moleculas relacionadas con el ligando para el receptor tnf inducido por glucorticoides (gitr) y el ligando (gitr) y usos de los mismos.
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
SI2231667T1 (sl) 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
PE20120010A1 (es) 2008-10-31 2012-02-07 Shionogi & Co Cefalosporinas que tienen un grupo catecol
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011061760A1 (en) 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
JP2012027846A (ja) 2010-07-27 2012-02-09 Sony Corp 情報処理装置、情報表示方法及びコンピュータプログラム
DK2646436T3 (en) * 2010-11-29 2015-06-29 Pfizer monobactams
MX357241B (es) 2011-08-25 2018-06-29 Merck Sharp & Dohme Inhibidores de fosfodiesterasa 10 de pirimidina.
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
MX2014011827A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc Inhibidores de 1,3,4 - oxadiazol y 1,3,4 - tiadiazol b-lactamasa.
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Also Published As

Publication number Publication date
AU2015236369B2 (en) 2017-02-16
EP3511328A1 (en) 2019-07-17
MY179292A (en) 2020-11-03
US20150266867A1 (en) 2015-09-24
TW201540712A (zh) 2015-11-01
US20190231752A1 (en) 2019-08-01
EP3122745B1 (en) 2019-02-27
PL3122745T3 (pl) 2019-08-30
HRP20190501T1 (hr) 2019-05-03
NZ723114A (en) 2020-12-18
ES2862203T3 (es) 2021-10-07
IL247259B (en) 2020-02-27
EA030850B1 (ru) 2018-10-31
US10369138B2 (en) 2019-08-06
AU2015236369A1 (en) 2016-09-01
LT3122745T (lt) 2019-04-10
CA2939254C (en) 2023-02-14
US9174978B2 (en) 2015-11-03
DK3122745T3 (en) 2019-04-08
PE20161371A1 (es) 2016-12-21
CN106164072A (zh) 2016-11-23
CN106164072B (zh) 2019-10-01
MA39777A (fr) 2017-02-01
RS58509B1 (sr) 2019-04-30
PH12016501577A1 (en) 2016-10-03
SI3122745T1 (sl) 2019-05-31
SMT201900218T1 (it) 2019-05-10
ES2719136T3 (es) 2019-07-08
BR112016020333B1 (pt) 2022-08-09
CL2016002285A1 (es) 2016-12-30
TWI714525B (zh) 2021-01-01
PH12016501577B1 (en) 2022-04-29
WO2015148379A1 (en) 2015-10-01
ECSP16073620A (es) 2018-12-31
SG11201606711UA (en) 2016-10-28
MX2016011822A (es) 2016-12-02
MX373444B (es) 2020-04-30
IL247259A0 (en) 2016-09-29
MA39777B1 (fr) 2019-03-29
EA201691766A1 (ru) 2016-12-30
UA121383C2 (uk) 2020-05-25
DK3511328T3 (da) 2021-03-22
US20160051523A1 (en) 2016-02-25
EP3122745A1 (en) 2017-02-01
US20200276169A1 (en) 2020-09-03
CU24441B1 (es) 2019-09-04
EP3511328B1 (en) 2021-03-03
JP2017510580A (ja) 2017-04-13
PT3122745T (pt) 2019-04-30
KR101733441B1 (ko) 2017-05-10
BR112016020333A2 (pt) 2017-10-24
JP6153674B2 (ja) 2017-06-28
HUE042134T2 (hu) 2019-06-28
AP2016009374A0 (en) 2016-08-31
KR20160110541A (ko) 2016-09-21
SV2016005274A (es) 2018-06-12
GT201600183A (es) 2018-12-18
CY1121701T1 (el) 2020-07-31
CA2939254A1 (en) 2015-10-01
ZA201605565B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
ECSP16073620A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
SV2017005462A (es) Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2015001084A1 (es) Compuestos derivados de cefem 2-sustituidos; composicion farmaceutica que los comprende; utiles como agentes efectivos contra bacterias gram negativas que producen beta-lactamasa, incluyendo bacterias resistentes a multiples farmacos, y/o bacterias gram positivas.
ECSP14013273A (es) Compuestos antibacterianos y métodos para su uso
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
MX376475B (es) Derivado de polimixina y usos del mismo.
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
UY36000A (es) ?compuestos microbicidas, método para controlar o prevenir la infestación de microorganismos fitopa togenos, y composición de los mismos?.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
ECSP19016602A (es) Inhibidores de beta-lactamasa
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
CR20160412A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
UY36043A (es) COMPUESTOS ORGÁNICOS DE MONOBACbTAM PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS